Blog

How Alpha Analyst is redefining investment research. Insights, team perspectives, and the latest on building AI for finance.

What Does Shopify (SHOP) Actually Do?

What Does Shopify (SHOP) Actually Do?

A plain-English map of Shopify’s commerce platform, how revenue is split, and what to track in SEC filings

What Does Meta (META) Actually Do?

What Does Meta (META) Actually Do?

A plain-English map of Meta’s two segments and how ads fund long-term bets in AI, wearables, and mixed reality

Meta acquires Manus for $2B: what it means for AI agents

Meta acquires Manus for $2B: what it means for AI agents

A practical investor-focused breakdown of the deal, the AI agent business model, and what to track next

What Does Coca-Cola (KO) Actually Do?

What Does Coca-Cola (KO) Actually Do?

A plain-English view of the concentrate model, bottler system, and what to monitor in Coca-Cola’s SEC filings

What Does Wells Fargo (WFC) Actually Do?

What Does Wells Fargo (WFC) Actually Do?

A plain-English map of the bank’s four segments, how earnings are made, and what to monitor in 10-Ks and 10-Qs

What Does Caterpillar (CAT) Actually Do?

What Does Caterpillar (CAT) Actually Do?

A plain-English map of Caterpillar’s end markets, segment engines, and what to monitor in the 10-K each quarter

What Does UnitedHealth Group (UNH) Actually Do?

What Does UnitedHealth Group (UNH) Actually Do?

A plain-English map of UnitedHealthcare vs Optum, how the four segments make money, and what to track in filings each quarter

What Does IBM (IBM) Actually Do?

What Does IBM (IBM) Actually Do?

A plain-English breakdown of IBM’s hybrid cloud and AI strategy, how each segment makes money, and what to track in filings

What Does Netflix (NFLX) Actually Do?

What Does Netflix (NFLX) Actually Do?

A plain-English map of the streaming model: how subscriptions and ads become revenue, what drives content spending, and what to track in filings

What Does AbbVie (ABBV) Actually Do?

What Does AbbVie (ABBV) Actually Do?

A plain-English map of the biopharma model: how a drug portfolio becomes revenue, what drives margins, and what to track in filings